---
layout: default
title: Riluzole
parent: Model Prediction Only (L5)
nav_order: 593
evidence_level: L5
indication_count: 10
---

# Riluzole
{: .fs-9 }

Evidence Level: **L5** | Predicted Indications: **10** 
{: .fs-6 .fw-300 }

---

## Table of Contents
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## Pharmacist Assessment Report

</div>

Using no additional skill here — this is a direct, fully-specified report-generation task with the template already given in the prompt; none of the available skills (debugging, brainstorming, code-review, etc.) apply.

A note before the report: `predicted_indications[0]` in this evidence pack is **Bilateral Parasagittal Parieto‑Occipital Polymicrogyria** — a congenital cortical malformation with `evidence_level: L5`, `decision_stage: S0`, `recommendation: Hold`, and no supporting trials or literature. Its own `repurposing_rationale` explicitly states there is no plausible mechanistic link to Riluzole. I've written the report accurately reflecting that this rank‑1 candidate is graph-similarity noise, rather than dressing it up as a promising lead. (Separately, note that rank‑8 "ALS, susceptibility to" in this pack is actually Riluzole's *existing* approved indication, not a new one — it is not used here since the template specifies index 0.)

---

# Riluzole: From Amyotrophic Lateral Sclerosis to Bilateral Parasagittal Parieto-Occipital Polymicrogyria

## One-Sentence Summary

Riluzole is an established neuroprotective agent for amyotrophic lateral sclerosis (ALS), acting via inhibition of glutamate release and blockade of voltage-gated sodium channels. The TxGNN model assigns a high similarity score to **Bilateral Parasagittal Parieto-Occipital Polymicrogyria**, a congenital cortical malformation, but this pairing is currently supported by **no clinical trials** and **no published literature**, and the model's own rationale flags it as lacking a plausible mechanistic basis.

## Quick Overview

| Item | Content |
|------|------|
| Original Indication | Amyotrophic Lateral Sclerosis (ALS) — based on public regulatory history; not present in the evidence pack's ARTG data |
| Predicted New Indication | Bilateral Parasagittal Parieto-Occipital Polymicrogyria |
| TxGNN Prediction Score | 99.99% |
| Evidence Level | L5 (model prediction only, no supporting studies) |
| Australia Market Status | Not Marketed |
| Number of ARTG Entries | 0 |
| Recommended Decision | Hold |

## Why is This Prediction Reasonable?

Detailed mechanism-of-action data was not available in this evidence pack (flagged as a data gap). Based on publicly known pharmacology, Riluzole inhibits presynaptic glutamate release and blocks voltage-gated sodium channels, an action believed to reduce excitotoxic injury to motor neurons. This mechanism underpins its approval for ALS, where Phase 3 trials (Bensimon 1994; Lacomblez 1996) demonstrated a modest survival benefit.

Bilateral parasagittal parieto-occipital polymicrogyria is a structural malformation of cortical development, typically arising from disrupted neuronal migration or genetic causes affecting cortical lamination during fetal development. This is pathophysiologically distinct from the neurodegenerative, excitotoxicity-driven process Riluzole targets in ALS.

The model's own repurposing rationale for this pairing states directly: *"a structural disorder of cortical development, with no plausible pathophysiological link to Riluzole's glutamate-modulating/sodium-channel-blocking mechanism; this is a pure knowledge-graph similarity artefact without substantive mechanistic support."* We have not identified an independent rationale that would override this assessment — the prediction should be treated as unvalidated graph-similarity output rather than a mechanistically grounded hypothesis.

## Clinical Trial Evidence

Currently no related clinical trials registered.

## Literature Evidence

Currently no related literature available.

## Safety Considerations

Riluzole is not currently marketed in Australia (0 ARTG entries), so no TGA-approved Product Information exists for local reference. Key warnings, contraindications, and drug interaction data were not available in this evidence pack (DDI query returned "not found"). Prescribers should consult overseas-approved labelling (e.g. FDA or EMA product information) for established Riluzole safety information — most notably its known hepatotoxicity risk, which requires liver function monitoring in its approved ALS use — before considering any off-label application.

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
There are no clinical trials, no literature, and no credible mechanistic rationale connecting Riluzole to this predicted indication. The evidence level (L5) reflects a model-only prediction, and the model's own generated rationale identifies the pairing as likely graph noise rather than a genuine repurposing signal.

**To proceed, the following is needed:**
- Confirmed mechanism-of-action detail from DrugBank or primary literature (currently a data gap)
- TFDA/TGA product information and warnings/contraindications (currently a data gap, marked Blocking)
- A biologically plausible mechanistic hypothesis linking Riluzole to disorders of cortical development, if one exists
- Any preclinical or case-level evidence, should future literature searches surface it
- Re-evaluation only if new trial or publication evidence emerges — no further action is warranted on current data
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

